News & Events
Meeting and exceeding your expectations
Forthcoming meetings and exhibitions
| Event | Dates | Location | Organiser Link |
|---|---|---|---|
| American Laboratory Automation (ALA) | 24-26th January | Palm Springs, CA. USA | www.labautomation.org |
| 26th Clinical Virology Symposium (CVS) | 25-28th April | Daytona Beach, FL. USA | www.virology.org/CVS.html |
| ISBT | 26 June - 1st July | Berlin, Germany | www.isbt-web.org |
| AACC | 25-29th July | Anaheim, CA. USA | www.aacc.org |
| AABB | 9-12th October | Baltimore, MD. USA | www.aabb.org |
News
Vacancy for Business Development Manager (N. America)
April 27, 2010
An exciting opportunity for a dynamic and ambitious person who would be responsible for growing our business and enhancing our presence in the USA blood screening and molecular diagnostics market. The role will involve working very closely with the existing support and management of Sanguin Inc. Significant travel within (and potentially outside the US) will be required. For more information contact proberts@sanguin.com
Birkenfeld, December 17, 2009
STRATEC Biomedical Systems, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard), has today published medium-term financial guidance based on recent clients’ forecasts and statements, allied to the Company’s current development pipeline. Current trading continues in line with management’s expectations, and STRATEC today reaffirms its previous guidance for 2009 and calls for revenue growth of between 20% and 30% (Euro 73.2 million to Euro 79.3 million).
For the financial year 2010, STRATEC expects sales in the range of Euro 96 million to Euro 102 million. Based on the stable growth of all programs, as well as the prospects and forecasts for the new programs, STRATEC expects to continue its growth for the coming years. Specifically, the compound annual growth rate (CAGR) for sales over the years 2010 to 2012 is expected to exceed 15%.“Our continuous growth trajectory is based on solid performance across all our major projects and on the development of new systems.” stated Hermann Leistner, CEO of STRATEC, adding: “Our leading position as an independent OEM supplier is strengthened by the continuous outsourcing trend in our industry as well as the strong demand for molecular diagnostics technologies and chemiluminescence assay analysers. STRATEC’s state of the art technologies, such as random access analyzers, meet the requirements of our customers to offer solutions fitting the modern laboratory and blood bank workflows.”